Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed stand...

متن کامل

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis. Patients with MMM have shortened survival and their quality of life is compromised by progressive anemia, marked hepatosplenomegaly, and severe constitutional...

متن کامل

New response criteria for lymphomas in clinical trials.

Standardized staging and response assessment are critical to the successful conduct of clinical trials. In turn, clinical trials are essential to the development of new and more effective therapy for patients with lymphomas. In the absence of effective agents, response criteria are almost irrelevant. However, with the increasing number of effective therapies, standardized criteria are necessary...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Blood

سال: 2019

ISSN: 0006-4971,1528-0020

DOI: 10.1182/blood-2018-06-857102